Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | PTPRB | P23467 | 1/20 | 0.49 |
| ▸ | CDC25A | P30304 | 1/20 | 0.49 |
| ▸ | CDC25B | P30305 | 1/20 | 0.49 |
| ▸ | PTEN | P60484 | 1/20 | 0.49 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17083287 | 0.84 | MEN1 (0.50) | FFAR1MEN1KMT2AMEP1B | |
| SCHEMBL14569569 | 0.82 | KEAP1 (0.55) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL11794365 | 0.81 | SLC2A1 (0.57) | MEN1KMT2AMEP1B | |
| SCHEMBL70271 | 0.81 | KEAP1 (0.74) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| Hydrochloric Acid SCHEMBL10982620 | 0.79 | KEAP1 (0.71) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL7357611 | 0.79 | KEAP1 (0.55) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL28750453 | 0.79 | KEAP1 (0.55) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL14558107 | 0.78 | FFAR1 (0.51) | FFAR1MEN1KMT2AMEP1B | |
| SCHEMBL12871186 | 0.78 | FFAR1 (0.55) | KEAP1PTPRBCDC25ACDC25BPTEN | |
| SCHEMBL17788675 | 0.78 | MEP1B (0.71) | MEP1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-08 | — | — | US | disclosed |
| US-7179819-B2 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054909-A1 | VLA-4 inhibitor compounds | VCAM1, ITGB4, ICAM1 | KEAP1 2081/4885PTPRB 651/4885CDC25A 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.